CRL — Clinical Research Labs
Back to catalog
ARA-290 (Cibinetide) 3ml vial label
RecoveryPurity 99.1%
Product profile

ARA-290 (Cibinetide)

Erythropoietin-derived peptide for tissue-protection research.

99.1%
Purity
Lyophilized
Form
-20°C
Storage
Research Use Only. Not for human or veterinary consumption, diagnostic, or therapeutic use.

What it is

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from the helix-B region of erythropoietin investigated for innate-repair and tissue-protection research.

Pathway Diagram

Mechanism of Action

CRL · MOA-01

Engages the heteromeric β-common/EPOR innate repair receptor without erythropoietic activity.

  1. Step 01
    Receptor Binding

    Peptide engages target receptor with high affinity.

  2. Step 02
    Signal Cascade

    Downstream intracellular pathways activate.

  3. Step 03
    Cellular Response

    Gene expression and protein synthesis shift.

  4. Step 04
    Observed Outcome

    Measurable change in the studied biomarker.

Primary TargetsNeuropathy researchAnti-inflammatory pathway studiesTissue protection models

Research highlights

Helix-B 11-mer derived from erythropoietin; no erythropoietic activity.
Engages the βcR/EPOR innate-repair receptor.
Reduces neuropathic pain and improves metabolic markers in T2D research.
Active across multiple inflammation and tissue-injury models.

Pharmacology snapshot

1257.4 Da
Molecular weight
~2 minutes (active metabolite signaling persists)
Half-life
SC (research)
Route (research)

Potential research applications

Neuropathy research
Anti-inflammatory pathway studies
Tissue protection models
Metabolic inflammation

Case studies

Preclinical—

Nonerythropoietic EPO peptide design

Cohort: Multiple tissue-injury models

Original work characterizing peptides from the helix-B region of EPO.

Outcome

Demonstrated tissue-protective effects without erythropoiesis.

Brines et al., PNAS 2008;105(31):10925–10930
Clinical28 days

T2D neuropathy improvement

Cohort: Adults with T2D & neuropathy

Phase 2 of ARA-290 on metabolic and neuropathy outcomes.

Outcome

Improved HbA1c, lipids and neuropathy symptom scores vs. placebo.

Brines et al., Mol Med 2014;20(1):658–666
Clinical28 days

Sarcoidosis small-fiber neuropathy

Cohort: Sarcoidosis patients

ARA-290 in patients with sarcoidosis-associated small-fiber loss.

Outcome

Significant improvement in pain and quality-of-life metrics.

Dahan et al., Mol Med 2013;19(1):334–345
Handling Protocol

Storage Guidelines

CRL · STR-02

Lyophilized -20°C, light-protected.

Lyophilized
-20°C
Long-term, 24 months
Reconstituted
2–8°C
Refrigerated, 28 days
Light Exposure
Protect
Store in dark vial
Diluent
BAC Water
Sterile, 0.9% benzyl
Best practice — reconstitute with bacteriostatic water, swirl gently, do not shake.
Regulatory Notice

Research Disclaimer

CRL · REG-03
Research Use Only

Strictly for in-vitro laboratory and research investigations.

Not For Human Use

Not approved for diagnostic, therapeutic, or veterinary application.

Qualified Personnel

Handling restricted to licensed researchers and laboratory staff.

Warning — ARA-290 (Cibinetide) is supplied solely for legitimate laboratory research. Any administration to humans or animals is strictly prohibited and may violate federal, state, or local law. By purchasing, the researcher accepts full responsibility for safe handling, storage, and lawful use.

Document · CRL-REG-03Revision 2026.06 · Clinical Research Labs
Representative Literature

Citations & References

CRL · REF-04
  1. 01
    Brines M, Patel NS, Villa P, et al. · 2008
    Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin
    PNAS. 105(31):10925–10930.
    DOI · 10.1073/pnas.0805594105PMID · 18676615
  2. 02
    Brines M, Dunne AN, van Velzen M, et al. · 2014
    ARA 290, a nonerythropoietic peptide engaging the innate repair receptor, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
    Mol Med. 20(1):658–666.
    DOI · 10.2119/molmed.2014.00215PMID · 25387363
  3. 03
    Dahan A, Dunne A, Swartjes M, et al. · 2013
    ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss
    Mol Med. 19(1):334–345.
    DOI · 10.2119/molmed.2013.00122PMID · 24136731
References are representative of peer-reviewed literature and are provided for research context only.
Document · CRL-REF-04Revision 2026.06 · Clinical Research Labs